New York, USA – August 16, 2021 – From the outbreak of the COVID-19 and the approval of the first vaccine against it, the entire health community has been working arduously. Now, the research on an effective therapeutic vaccine against the COVID-19 is also urging. Creative Biolabs, as a specialized solution provider in vaccine development, is fully capable to support customers’ projects with its specialties in the design, formulation development, analysis, and evaluation of various vaccine types.
The specialties in recombinant DNA technology, genomics, and immunology enable Creative Biolabs to design a vaccine using adenovirus as a vector through two strategies, which are homologous recombination in mammalian systems and direct molecular cloning of the adenoviral genome.
Adeno-associated Virus (AAV) Vector Vaccines
The technicians design and manufacture the AAV viral vector by adjusting the expression of key factors such as host cell lines, promoters, and regulatory elements, to produce the vectors that are non-pathogenic, have low inflammatory potential, and are available for viral serotypes with different tissue tropisms. Commonly adopted expression systems to produce AAV vectors are adenovirus, herpesvirus, baculovirus complementary systems, and yeast expression systems.
Live Attenuated Vaccines
As one of the FDA-approved COVID-19 vaccine types, live attenuated vaccine has drawn much attention, which is created by reducing the virulence of a pathogen, but still keeping it viable. Technicians support the design of both live attenuated vaccine and killed vaccine. To fix the questionable safety issues, Creative Biolabs manipulate the radiation technology to attenuate and kill the virus, which is characterized by high dose irradiator, superior dose selection capacity, mutant selection, genome sequencing, and other insuring factors.
“Although we already have the vaccines that protect us from SARS-CoV-2, the emerging variants still require more powerful vaccines,” a scientist at Creative Biolabs commented, “and vaccine can also be an effective therapeutic tool.”
Aside from the discovery and development, analytical development & qualification and preclinical assessment are also part of the development solutions. Learn more about the capabilities and solutions at https://www.creative-biolabs.com/vaccine.
About the Enterprise
Creative Biolabs is a CRO run by a group of scientists who have specialties in chemistry, biology, biotechnology, molecular science, and so on. With years of experience in vaccine development, Creative Biolabs has launched a center that specifically offers services and products for those clients working on vaccine preclinical studies. The annually growing orders and returned customers prove the strength of this enterprise as fully potential.